Given that clinical trials have shown limited clinical benefit with immunotherapy (primarily immune checkpoint inhibitors (ICIs)) as monotherapy in EGFR-mutated NSCLC [12,13], and that combining ICIs with EGFR TKIs is associated with increased toxicity [14,15], these findings highlight a significant unmet need in this patient population. This evidence concerns the gene EGFR and non-small cell lung carcinoma.